GO:0002840 regulation of T cell mediated immune response to tumor cell: Immune Evasion, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002840 describes any process that modulates the frequency, rate, or extent of a T cell mediated immune response to tumor cells, encompassing both positive and negative regulation.
• Cancer cells can actively impair monocyte-mediated T cell stimulation, a key evasion mechanism that dampens the T cell response to tumors.
• Checkpoint blockade with anti-CTLA-4 or anti-PD-1 antibodies enhances T cell mediated tumor killing by removing inhibitory signals.
• Loss of SGK1 in hepatocellular carcinoma promotes resistance to T cell-mediated immunity and supports metastatic colonization.
• Fas-mediated off-target tumor killing is a critical component of T cell immunotherapy efficacy, highlighting the importance of death receptor signaling in this process.
• Dietary elaidic acid boosts tumoral antigen presentation via ACSL5, thereby enhancing T cell mediated immune responses against cancer.
Description
The Gene Ontology term GO:0002840, regulation of T cell mediated immune response to tumor cell, defines any biological process that modulates the frequency, rate, or extent of a T cell mediated immune response directed against tumor cells. This term captures the complex interplay between tumor cells, antigen-presenting cells, and T lymphocytes, where positive regulation can lead to tumor eradication and negative regulation can result in immune evasion and cancer progression. Understanding this regulatory network is fundamental for developing effective cancer immunotherapies, as interventions that boost T cell activity against tumors have shown remarkable clinical success. Researchers studying this process investigate how tumors escape immune surveillance, how checkpoint inhibitors work, and how metabolic or genetic factors influence T cell function within the tumor microenvironment. The term is particularly relevant for studies on adoptive T cell therapy, immune checkpoint blockade, and cancer vaccines, where the goal is often to enhance the magnitude and quality of T cell mediated tumor killing.
regulation of T cell mediated immune response to tumor cell At A Glance
| GO ID | GO:0002840 |
|---|---|
| GO term | regulation of T cell mediated immune response to tumor cell |
| Ontology | biological_process |
| Synonym | regulation of T-cell mediated immune response to tumor cell; regulation of T cell mediated immune response to tumour cell; regulation of T lymphocyte mediated immune response to tumor cell; regulation of T-lymphocyte mediated immune response to tumor cell |
| Major function | Modulates the frequency, rate, or extent of T cell mediated killing of tumor cells |
| Related processes | T cell activation, antigen presentation, immune checkpoint signaling, cytokine production |
| Disease relevance | Cancer immunotherapy, autoimmune diseases, chronic infections |
| Key cell types | CD8+ cytotoxic T cells, CD4+ helper T cells, regulatory T cells, antigen-presenting cells, tumor cells |
What Is GO:0002840?
GO:0002840 is a biological process term that encompasses any mechanism which adjusts the frequency, rate, or extent of a T cell mediated immune response to tumor cells. This includes both stimulatory and inhibitory signals that originate from tumor cells, antigen-presenting cells, or the T cells themselves, ultimately shaping whether T cells effectively recognize and destroy malignant cells.
Why Is regulation of T cell mediated immune response to tumor cell Important in Cell Biology?
Regulation of T cell mediated immune response to tumor cells is central to cancer immunology because it determines whether the immune system can eliminate malignant cells or whether tumors escape destruction. This process is the basis for the clinical success of immune checkpoint inhibitors, which block negative regulators such as CTLA-4 and PD-1 to enhance T cell activity against tumors. Conversely, tumors can hijack regulatory mechanisms to suppress T cell function, as seen when cancer cells impair monocyte-mediated T cell stimulation or when loss of SGK1 promotes resistance to T cell immunity in hepatocellular carcinoma. Understanding these regulatory pathways is essential for identifying biomarkers of response, developing combination therapies, and overcoming resistance to immunotherapy.
• Determines the efficacy of immune checkpoint blockade in melanoma, lung cancer, and hepatocellular carcinoma.
• Underlies mechanisms of tumor immune evasion, including impaired antigen presentation and T cell stimulation.
• Influences metastatic colonization, as shown by SGK1 loss promoting resistance to T cell-mediated immunity in HCC.
• Involves cytokine networks, such as IL-17-producing γδ T cells and neutrophils that promote breast cancer metastasis.
• Fas-mediated off-target tumor killing is a critical effector mechanism in T cell immunotherapy.
• Dietary factors like elaidic acid can boost antigen presentation and enhance T cell responses via ACSL5.
• Provides targets for combination therapies, e.g., lenvatinib plus anti-PD-1 in HCC.
• Guides development of personalized immunotherapies based on tumor microenvironment composition.
• Helps explain sex differences and heterogeneity in immunotherapy responses.
• Supports discovery of novel biomarkers for predicting patient outcomes.
What Happens During regulation of T cell mediated immune response to tumor cell?
Tumor Antigen Recognition and Presentation
In simple terms: T cells need to see tumor antigens presented by other cells to become activated.
The process begins when tumor antigens are taken up by antigen-presenting cells (APCs) such as dendritic cells and monocytes, processed, and presented on MHC molecules to T cells. Cancer cells can impair this step; for example, they can disrupt monocyte-mediated T cell stimulation, leading to immune evasion. Enhancing antigen presentation, such as through dietary elaidic acid via ACSL5, can boost tumoral antigen presentation and strengthen T cell mediated immunity.
T Cell Activation and Costimulation
In simple terms: T cells require additional signals beyond antigen recognition to become fully active.
Upon antigen recognition, T cells require costimulatory signals (e.g., via CD28) and cytokine support to proliferate and acquire effector functions. Negative regulators like CTLA-4 compete with CD28 for ligands and dampen T cell activation; blocking CTLA-4 with antibodies enhances antitumor immunity. Similarly, the PD-1/PD-L1 axis inhibits T cell receptor signaling, and PD-1 blockade can restore T cell function in tumors.
Effector Mechanisms of T Cell Mediated Killing
In simple terms: Activated T cells directly kill tumor cells through death ligands and cytotoxic granules.
Effector T cells eliminate tumor cells via multiple mechanisms, including Fas-FasL mediated apoptosis. Fas-mediated off-target tumor killing has been identified as a critical component of T cell immunotherapy, contributing to tumor regression even when antigen specificity is not perfect. Cytotoxic granules containing perforin and granzymes also play a major role, though the relative contribution can vary by tumor type.
Regulation by the Tumor Microenvironment
In simple terms: The tumor and surrounding cells can suppress T cell activity.
The tumor microenvironment contains immunosuppressive cells such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages that secrete inhibitory cytokines (e.g., IL-10, TGF-β) and metabolites. IL-17-producing γδ T cells and neutrophils can conspire to promote breast cancer metastasis by suppressing antitumor immunity. Additionally, loss of SGK1 in hepatocellular carcinoma cells promotes resistance to T cell-mediated immunity, facilitating metastatic colonization.
Checkpoint Regulation and Therapeutic Intervention
In simple terms: Checkpoint inhibitors release the brakes on T cells to enhance tumor killing.
Immune checkpoints like CTLA-4 and PD-1 are negative regulators of T cell responses. Blocking CTLA-4 enhances antitumor immunity in preclinical models, and PD-1 blockade induces responses in melanoma by inhibiting adaptive immune resistance. Combining checkpoint inhibitors with targeted therapies, such as lenvatinib (an FGFR4 inhibitor) plus anti-PD-1, can further enhance antitumor immune responses in hepatocellular carcinoma.
Key Genes Involved in GO:0002840 regulation of T cell mediated immune response to tumor cell
The following genes and proteins are critically involved in regulating T cell mediated immune responses to tumor cells, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTLA-4 | Negative regulator of T cell activation; competes with CD28 for ligands | Target of ipilimumab; enhances antitumor immunity when blocked |
| PD-1 (PDCD1) | Inhibitory receptor on T cells; induces adaptive immune resistance | Target of pembrolizumab/nivolumab; predicts response to PD-1 blockade |
| SGK1 | Serum/glucocorticoid-regulated kinase; promotes resistance to T cell-mediated immunity | Loss supports metastatic colonization in HCC; potential therapeutic target |
| ACSL5 | Acyl-CoA synthetase; boosts tumoral antigen presentation | Dietary elaidic acid enhances cancer immunity via ACSL5 |
| FAS | Death receptor mediating off-target tumor killing by T cells | Critical for T cell immunotherapy efficacy |
| IL-17A | Pro-inflammatory cytokine produced by γδ T cells; promotes metastasis | IL-17-producing γδ T cells and neutrophils promote breast cancer metastasis |
| FGFR4 | Fibroblast growth factor receptor 4; target of lenvatinib | Lenvatinib enhances anti-PD-1 response in HCC via FGFR4 |
| CD8A | Marker of cytotoxic T cells; mediates tumor killing | Central to T cell mediated immune response to tumors |
| CD4 | Marker of helper T cells; supports cytotoxic T cell function | Modulates antitumor immunity |
| IFNG | Interferon gamma; enhances antigen presentation and T cell recruitment | Key effector cytokine in antitumor immunity |
| TNF | Tumor necrosis factor; promotes inflammation and tumor cell apoptosis | Contributes to T cell mediated tumor killing |
| GZMB | Granzyme B; serine protease in cytotoxic granules | Mediates target cell apoptosis |
| PRF1 | Perforin; forms pores in target cell membranes | Essential for granule-mediated killing |
| FOXP3 | Regulatory T cell transcription factor; suppresses antitumor immunity | Depletion enhances T cell responses |
| CD274 (PD-L1) | Ligand for PD-1; expressed on tumor cells and APCs | Mediates adaptive immune resistance |
| CD80 | Costimulatory ligand for CD28 and CTLA-4 | Modulates T cell activation |
| CD86 | Costimulatory ligand for CD28 and CTLA-4 | Modulates T cell activation |
| CCL2 | Chemokine recruiting monocytes/macrophages | Impacts monocyte-mediated T cell stimulation |
How Is regulation of T cell mediated immune response to tumor cell Regulated?
The regulation of T cell mediated immune response to tumor cells is controlled by a network of stimulatory and inhibitory signals. Checkpoint molecules such as CTLA-4 and PD-1 provide inhibitory regulation, and their blockade enhances antitumor immunity. Tumor-derived factors can also regulate this process; for instance, cancer cells can impair monocyte-mediated T cell stimulation to evade immunity. Metabolic and signaling pathways, such as SGK1, modulate resistance to T cell-mediated killing. Additionally, dietary components like elaidic acid can positively regulate antigen presentation and T cell responses via ACSL5. Cytokines such as IL-17 produced by γδ T cells can promote metastasis by altering the immune microenvironment. These diverse regulatory inputs collectively determine the outcome of T cell mediated tumor surveillance.
regulation of T cell mediated immune response to tumor cell and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SGK1 | Hepatocellular carcinoma metastasis and resistance to T cell immunity | SGK1 knockout HCC cell lines in immunocompetent mouse models |
| ACSL5 | Cancer immunity and antigen presentation | ACSL5 overexpression or knockout in tumor cells with dietary intervention |
| FAS | T cell immunotherapy efficacy and off-target tumor killing | Fas knockout tumor cells in adoptive T cell transfer models |
| IL-17A | Breast cancer metastasis | IL-17A knockout mice or γδ T cell depletion in breast cancer models |
| FGFR4 | Hepatocellular carcinoma response to anti-PD-1 | FGFR4 knockout or inhibition in HCC models combined with anti-PD-1 |
Cancer Immune Evasion and Progression
Dysregulation of T cell mediated immune responses to tumors is a hallmark of cancer progression. Tumors can evade T cell killing by impairing antigen presentation, upregulating checkpoint ligands, or recruiting immunosuppressive cells. For example, cancer cells can impair monocyte-mediated T cell stimulation, leading to immune evasion. Loss of SGK1 in hepatocellular carcinoma promotes resistance to T cell-mediated immunity and supports metastatic colonization. In breast cancer, IL-17-producing γδ T cells and neutrophils conspire to promote metastasis by suppressing antitumor immunity.
Immunotherapy Response and Resistance
The efficacy of cancer immunotherapy depends on the regulation of T cell mediated immune responses. PD-1 blockade induces responses in melanoma by inhibiting adaptive immune resistance. CTLA-4 blockade enhances antitumor immunity in preclinical models. Combining targeted therapies like lenvatinib with anti-PD-1 can enhance antitumor immune responses in hepatocellular carcinoma. However, resistance mechanisms, such as Fas-mediated off-target killing defects, can limit immunotherapy efficacy.
Metabolic and Dietary Influences
Metabolic factors can modulate T cell mediated immunity against tumors. Dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5, suggesting that nutritional interventions could enhance immunotherapy. This highlights the interplay between metabolism and immune regulation in cancer.
From regulation of T cell mediated immune response to tumor cell-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate T cell mediated tumor killing? | Knockout of gene X in tumor cells or T cells, followed by co-culture or in vivo tumor challenge |
| Does a point mutation in gene Y affect T cell activation? | Point-mutation knock-in of the mutation in cell lines or mice, then assess T cell responses |
| Does overexpression of gene Z enhance antitumor immunity? | Overexpression of gene Z in tumor cells or APCs, then measure T cell activation and tumor growth |
| Does a tagged version of protein W localize to immune synapses? | Tagged knock-in (e.g., GFP) of gene W, then imaging in T cell-tumor co-cultures |
| Does gene V regulate antigen presentation? | Knockout of gene V in APCs, then assess MHC presentation and T cell stimulation |
| Does a SNP in gene U affect immunotherapy response? | Knock-in of the SNP in model cell lines, then test response to checkpoint blockade |
How to Study the regulation of T cell mediated immune response to tumor cell Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on T cell mediated killing | Identify negative regulators of antitumor immunity |
| CRISPR activation screen | Gain-of-function effects on T cell mediated killing | Identify positive regulators or resistance mechanisms |
| Flow cytometry | T cell activation markers, cytokine production, degranulation | Assess T cell function after genetic perturbation |
| Cytotoxicity assay | Tumor cell killing by T cells | Quantify effector function of T cells |
| Syngeneic mouse models | In vivo tumor growth and immune response | Test gene function and therapies in immunocompetent hosts |
| Single-cell RNA-seq | Transcriptomic profiles of individual cells | Discover immune cell states and regulatory networks |
| Spatial transcriptomics | Gene expression with spatial context | Map tumor-immune interactions in situ |
| Proteomics | Protein expression and modifications | Identify signaling changes in T cells or tumor cells |
CRISPR Screens to Identify Regulators
Genome-wide CRISPR knockout or activation screens in tumor cells or T cells can identify genes that regulate T cell mediated killing. These screens typically use co-culture systems with cytotoxic T cells and readouts of tumor cell viability or reporter expression. Hits can be validated individually using knockout or overexpression models.
Flow Cytometry and Cytotoxicity Assays
Flow cytometry is used to measure T cell activation markers (e.g., CD69, CD25), cytokine production (e.g., IFN-γ, TNF), and degranulation (CD107a). Cytotoxicity assays, such as chromium release or Incucyte-based killing assays, quantify the ability of T cells to kill tumor cells. These methods are standard for assessing regulation of T cell mediated immune responses.
In Vivo Tumor Models
Syngeneic mouse tumor models (e.g., B16 melanoma, MC38 colon cancer) allow assessment of T cell mediated immunity in an immunocompetent host. Tumor growth, survival, and immune cell infiltration are monitored. Genetic knockouts or treatments (e.g., checkpoint inhibitors) can be tested for their impact on antitumor immunity.
Single-Cell RNA Sequencing and Spatial Transcriptomics
Single-cell RNA sequencing of tumor-infiltrating immune cells reveals heterogeneity in T cell states and regulatory networks. Spatial transcriptomics adds location information, showing how tumor cells and immune cells interact in situ. These technologies help identify regulatory mechanisms and biomarkers of response to immunotherapy.
How CRISPR Can Be Used to Study GO:0002840 regulation of T cell mediated immune response to tumor cell
Knockout
CRISPR knockout is used to delete genes in tumor cells or T cells to determine their role in regulating T cell mediated immune responses. For example, knocking out SGK1 in hepatocellular carcinoma cells can test its role in resistance to T cell immunity. Knockout of Fas in tumor cells can reveal the importance of Fas-mediated killing in immunotherapy.
Point Mutation
Point mutations can be introduced via CRISPR to model specific amino acid changes that affect protein function. This is useful for studying how mutations in genes like CTLA-4 or PD-1 affect T cell regulation. For instance, point mutations in the PD-1 gene can alter its binding to PD-L1 and impact T cell inhibition.
Knock-in
Knock-in of reporter genes (e.g., GFP) or tags allows visualization and tracking of proteins involved in T cell mediated immunity. Knock-in of a tag into the endogenous locus of a gene like IFNG can monitor cytokine production in real time. This approach preserves endogenous regulation and provides accurate readouts.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can be used to increase expression of genes that enhance T cell mediated immunity. For example, overexpressing ACSL5 in tumor cells can boost antigen presentation and T cell responses. Overexpression of costimulatory molecules like CD80 can enhance T cell activation.
How EDITGENE Supports regulation of T cell mediated immune response to tumor cell Research
Researchers studying regulation of T cell mediated immune response to tumor cell-related genes often need to determine whether a candidate gene is causally involved in modulating T cell activity against tumors. This requires precise genetic models to dissect the contribution of specific genes, mutations, or expression changes in tumor cells, antigen-presenting cells, or T cells themselves. EDITGENE provides a comprehensive suite of CRISPR-based services to generate such models efficiently and reliably.
Contact EDITGENE today to design your custom CRISPR model for regulation of T cell mediated immune response to tumor cell research.
Frequently Asked Questions About regulation of T cell mediated immune response to tumor cell
What is GO:0002840 regulation of T cell mediated immune response to tumor cell?
GO:0002840 is a Gene Ontology biological process term that describes any process that modulates the frequency, rate, or extent of a T cell mediated immune response to tumor cells. It includes both positive and negative regulation, such as checkpoint inhibition or enhancement of antigen presentation.
What genes are involved in regulation of T cell mediated immune response to tumor cell?
Key genes include CTLA-4, PD-1 (PDCD1), SGK1, ACSL5, FAS, IL-17A, FGFR4, and many others that influence T cell activation, antigen presentation, and tumor killing.
How do cancer cells evade T cell mediated immune responses?
Cancer cells can impair monocyte-mediated T cell stimulation, upregulate checkpoint ligands like PD-L1, recruit immunosuppressive cells, and alter antigen presentation. For example, cancer cells impair monocyte-mediated T cell stimulation to evade immunity.
What is the role of PD-1 in T cell mediated immune response to tumors?
PD-1 is an inhibitory receptor on T cells that, upon binding to PD-L1 on tumor cells, dampens T cell activation. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
How does CTLA-4 regulate antitumor immunity?
CTLA-4 is a negative regulator that competes with CD28 for costimulatory ligands. Blocking CTLA-4 enhances antitumor immunity.
What is the role of SGK1 in hepatocellular carcinoma?
Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity.
Can diet influence T cell mediated immune response to tumors?
Yes, dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5, suggesting that nutritional factors can modulate antitumor immunity.
What is Fas-mediated off-target tumor killing?
Fas-mediated off-target tumor killing is a mechanism by which T cells kill tumor cells independently of specific antigen recognition, and it is critical for T cell immunotherapy efficacy.
How do γδ T cells and neutrophils promote breast cancer metastasis?
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis by suppressing antitumor immunity.
What experimental models are used to study regulation of T cell mediated immune response to tumor cell?
Common models include CRISPR knockout or overexpression in tumor cells or T cells, syngeneic mouse tumor models, co-culture cytotoxicity assays, and single-cell RNA sequencing.
Conclusion
GO:0002840 regulation of T cell mediated immune response to tumor cell is a central biological process in cancer immunology, encompassing diverse mechanisms that either promote or suppress T cell activity against tumors. Understanding these regulatory pathways has led to breakthrough immunotherapies such as checkpoint inhibitors and continues to drive research into resistance mechanisms and combination strategies. By leveraging CRISPR-based models and screening technologies, researchers can dissect the precise roles of individual genes and pathways, accelerating the development of next-generation cancer immunotherapies.
References
- 1. Elewaut A et al.. 2025. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.. Nature 637(8046):716-725 PMID: 39604727
- 2. Leach DR et al.. 1996. Enhancement of antitumor immunity by CTLA-4 blockade.. Science 271(5256):1734-6 PMID: 8596936
- 3. Zhang Z et al.. 2025. Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity.. J Hepatol 83(2):397-410 PMID: 39892819
- 4. Tumeh PC et al.. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance.. Nature 515(7528):568-71 PMID: 25428505
- 5. Yi C et al.. 2021. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.. Hepatology 74(5):2544-2560 PMID: 34036623
- 6. Coffelt SB et al.. 2015. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.. Nature 522(7556):345-348 PMID: 25822788
- 7. Upadhyay R et al.. 2021. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.. Cancer Discov 11(3):599-613 PMID: 33334730
- 8. Lai Y et al.. 2024. Dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5.. Cell Metab 36(4):822-838.e8 PMID: 38350448
